Natco Pharma Limited — Others, 21-02-2025: Action(s) initiated or orders passed

NATCO Pharma has received orders from the Additional Director of Income Tax (International Taxation)-2, imposing a demand of ₹99.88 crore and ₹140.91 crore for TDS and interest related to assessment years 2018-19 and 2019-20. The company contends that this demand is arbitrary and plans to appeal the decision. Management assures that this order will not materially impact the company’s financials or operations. Investors may interpret this update with a neutral outlook, as it reflects management's confidence in contesting the claim while not affecting current business performance.